PHARMACY

Pending court ruling, Teva to delay marketing Temodar generic

BY Alaric DeArment

JERUSALEM Teva Pharmaceutical Industries will start marketing its version of a brain tumor drug only if the Federal Circuit of the U.S. District Court upholds a ruling that declared the branded version’s patent unenforceable, Teva announced Wednesday.

The generic drug maker said it had entered an agreement with Schering, now part of Merck & Co., whereby it will market the drug only if the Federal Circuit upholds the U.S. District Court for the District of Delaware’s January ruling that would allow Teva to market a generic version of Schering’s Temodar (temozolomide). The regulatory approval application for the drug was originally filed by Barr Labs, which Teva acquired in 2008.

The agreement also gives Teva to begin selling its version of the drug in August 2013.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

NCPA: Drug manufacturers should pay rebates in DoD’s Tricare program

BY Allison Cerra

ALEXANDRIA, Va. The National Community Pharmacists Association expressed support of the U.S. Department of Defense’s efforts to collect the same manufacturer rebates for the Tricare retail pharmacy program that are applicable to prescriptions filled at Tricare mail-order pharmacies and military treatment facilities.

Tricare beneficiaries may lose face-to-face interaction with their pharmacists if such reimbursements are not provided to them, NCPA said. Currently, prescriptions used in the Tricare retail pharmacy network are subject to federal ceiling prices under law. NCPA believes that the DoD shouldn’t be denied billions of dollars in rebates from drug manufacturers, or make Tricare members solely use mail-order prescriptions.

“The Department of Defense provides prescription drug benefits to active duty, reserve, and retired military families and wants to reduce cost, maintain access and produce the best health outcomes possible,” said Bruce Roberts, NCPA EVP and CEO. “However, drug manufacturers undercut those goals by not paying their fair share of federal ceiling prices. Studies indicate pharmacists are critical to patients in impacting medication adherence, but if drug manufacturers continue to only pay rebates for mail order prescriptions then that won’t occur. The Department of Defense should hold the drug manufacturers accountable for all their financial obligations.

“Without changes, the choice Tricare beneficiaries take for granted about where to get their prescription drugs might fall by the wayside as increased use of mail order would become an unfortunate, but possible reality,” added Roberts.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Report: Lilly drugs stolen out of warehouse

BY Alaric DeArment

HARTFORD, Conn. Burglars stole $70 million worth of prescription drugs from an Eli Lilly warehouse, according to published reports.

The Associated Press reported Tuesday that the burglars disabled the alarm, climbed the wall, cut a hole in the roof and rappelled inside the warehouse, in Enfield, Conn. Drugs stolen included anti-depressants and anti-psychotics, though there were no painkillers in the warehouse. Law enforcement officials told AP that they stole enough to fill a tractor-trailer.

The FBI has been called to investigate, AP reported.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES